Abstract The endogenous protein antizyme inhibitor (AZI) is a potential oncogene which promotes cell growth by both inhibiting antizyme (AZ) activity and releasing ornithine decarboxylase (ODC) from AZ-mediated degradation. High levels of ODC and polyamines are associated with numerous types of neoplastic transformation, and the genomic region including AZI is frequently amplified in tumors of the ovary and prostate. To determine whether AZI functionally promotes prostate tumor growth, we made PC3M-LN4 (human) and AT6.1 (rat) cancer cell lines stably expressing shRNA to knockdown antizyme inhibitor 1 (AZI). AZI knockdown was confirmed by western blot, quantitative real-time PCR, and immunofluorescence. To examine the ability of these cells to form tumors in vivo, 1 9 10 6 cells were injected subcutaneously into nude mice either with (PC3M-LN4) or without (AT6.1) Matrigel. Tumor growth was measured two times per week by caliper. We found that cells in which AZI levels had been knocked down by shRNA formed significantly smaller tumors in vivo in both human and rat prostate cancer cell lines. These results suggest that not only does AZI promote tumor growth, but also that AZI may be a valid therapeutic target for cancer treatment.
Introduction
Antizyme inhibitor (AZI) is an endogenous protein which has been studied primarily due to its critical role in regulating polyamine biosynthesis. Polyamines are multivalent, organic cations which are essential for a variety of processes including normal cell growth, gene regulation, differentiation, and development (Gerner and Meyskens 2004; Basuroy and Gerner 2006; Pegg 2006; Kahana et al. 2005; Agostinelli et al. 2010) . Polyamines are produced in a ratelimiting reaction catalyzed by the enzyme ornithine decarboxylase (ODC) (Pegg 2006) , and ODC activity is primarily controlled by the balance between antizyme (AZ) and antizyme inhibitor (AZI) within the cell (Coffino 2001a) . Antizyme, a tumor suppressor gene, acts as a negative regulator of the polyamine biosynthetic pathway, and production of antizyme protein is induced by high polyamine levels within the cell (Matsufuji et al. 1995) . Antizyme inhibits polyamine synthesis not only by binding to ODC and preventing polyamine uptake, but also by targeting ODC for degradation (Mangold 2006; Keren-Paz et al. 2007; Coffino 2001a, b; Murakami et al. 1992 Murakami et al. , 1996 Li and Coffino 1992) . AZI, a potential oncogene, prevents AZ from inducing ODC degradation resulting in elevated cellular polyamine levels.
Increased ODC activity and elevated polyamine levels have been associated with numerous types of neoplastic transformation including intraepithelial neoplasias, the non-invasive precursors of epithelial cancers (Nishioka et al. 1995) . ODC overexpression is also sufficient to transform mouse NIH-3T3 cells, and promote tumor growth in vivo (Auvinen et al. 1992) , and these findings have been validated in several additional mouse models. Transgenic K6/ODC or K5/ODC mice overexpressing ODC from the keratin 6 or keratin 5 promoter, respectively, develop spontaneous squamous neoplasms, and treatment of these tumors with DFMO (difluoromethylornithine), an ODC inhibitor, leads to rapid tumor regression (Peralta Soler et al. 1998; Megosh et al. 1995; Smith et al. 1998; Lan et al. 2000) . Based on its critical role in regulating cell growth and transformation, there has been long-term interest in targeting ODC as a tumor treatment, and several ODC inhibitors are now in clinical trials (Levin et al. 2003; Bachrach 2004; Bailey et al. 2010 ; Thompson et al. 2010; Zell et al. 2009; Meyskens et al. 2008) .
Although elevated ODC activity and high polyamine levels are frequently associated with neoplastic transformation (Gerner and Meyskens 2004; Shantz and Levin 2007) , very few studies to date have focused directly on the role of AZI in this process. Recent data has shown that AZI overexpression is sufficient to transform NIH-3T3 cells resulting in both increased cell proliferation and increased ODC activity (Keren-Paz et al. 2006) . Furthermore, NIH-3T3 cells overexpressing AZI formed tumors in vivo after subcutaneous injection into nude mice, while control cells did not (Keren-Paz et al. 2006) . AZI levels have also been directly linked to rates of cell proliferation through knockdown experiments. Knockdown of AZI in A549 cells with siRNA resulted in decreased cell growth and decreased ODC activity in vitro, although the ability of these cells to form tumors in vivo was not determined (Choi et al. 2005) . These preliminary studies suggest that modulating AZI expression may have a significant effect on tumor growth in vivo.
The genomic region including AZI has been found to be amplified in several tumor types including those of the ovary and prostate (Schaner et al. 2003 (Schaner et al. , 2005 van Duin et al. 2005) , and AZI overexpression has been demonstrated in gastric tumors (Jung et al. 2000) . Current data from Oncomine also suggest that AZI is upregulated in cancerous tissue from the breast, liver, skin, ovary, and cervix. Furthermore, AZI has been shown to be able to prevent AZ-mediated degradation of cyclin D1 (Newman et al. 2004) , providing a second direct link between AZI levels and rates of cell proliferation. In addition, numerous studies have analyzed the effect of polyamine analogues in prostate cancer cell lines. Treatment with the polyamine analogues DENSPM, BE-4-4-4-4, or CGP-48664 led to the inhibition of cell growth in a variety of androgen-independent prostate cancer cell lines, including AT6.1 and PC3 cells (Zagaja et al. 1998; Mi et al. 1998 ). In addition, animals with PC3 xenograft tumors exhibited decreased tumor growth following treatment with BE-4-4-4-4 (Mi et al. 1998) . Together, these data suggest that increased AZI may be an important determinant in cell transformation and subsequent tumorigenesis.
To further explore the role of AZI in promoting tumor growth in vivo, we made a series of prostate cancer cell lines stably expressing shRNA (short hairpin RNA) to knockdown antizyme inhibitor 1 (AZI) or control shRNA. Our results demonstrate that suppression of AZI levels in prostate cancer cell lines results in repression of cell proliferation in vitro, and repression of tumor growth in vivo. These results suggest that in vivo suppression of AZI may be a worthwhile strategy for anti-cancer therapy.
Materials and methods
Cell culture and growth curves PC3M-LN4 prostate cancer cells were maintained in RPMI media (Invitrogen) supplemented with 10% FBS (fetal bovine serum) and 1% GPS (glutathione/penicillin/streptomycin). PC3M-LN4 is a human, androgen-independent, highly metastatic cell line derived by serial inoculation of cells into the prostate followed by isolation of lymph node metastases. AT6.1 prostate cancer cells were maintained in RPMI media with 10% FBS, 1% GPS, and 250 nM dexamethasone (Sigma-Aldrich) as previously described. AT6.1 is an androgen-independent highly metastatic variant of Dunning rat R3327 cells, and was isolated by serial transplantation in Copenhagen rats. All cells were grown at 37°C in a humidified atmosphere with 5% CO 2 .
shRNA plasmids to knockdown human and mouse AZI were obtained from Origene. Each shRNA set contained empty vector pRS plasmid, non-effective shRNA to knockdown GFP, or four individual shRNA sequences to knockdown AZI. shRNA plasmids were tested for knockdown efficacy in each cell line, and the two shRNA sequences which gave the greatest degree of knockdown were chosen for further experiments. For human PC3M-LN4 cells, shAZI H81 and shAZI H84 which both target human AZI, were selected. For rat AT6.1 cells, shAZI H83 and shAZI M35 were chosen since they target regions of human and mouse AZI, respectively, that are conserved in the rat gene. A summary of the shRNA sequences used is shown in Table 1 .
To make stable cell lines, cells were plated in 6-well plates (4 9 10 5 cells/well for PC3M-LN4, and 2.5 9 10 5 cells/ well for AT6.1) and transfected the following day with pRS, shGFP, and shAZI plasmids using Lipofectamine 2000 (Invitrogen), according to manufacturer's protocol (1 lg shRNA/well and 5 ll Lipofectamine). The following day selection media containing either 2 lg/ml puromycin (PC3M-LN4 cells) or 26 lg/ml puromycin (AT6.1 cells) was added. Following 2 weeks in selection media, stable non-clonal pools were established.
To compare rates of cell growth in vitro, PC3M-LN4 and AT6.1 cells stably expressing pRS control vector, shGFP control vector, or shAZI plasmids were plated at 1 9 10 4 cells/well in 6-well plates. Each day, duplicate wells of each cell line were collected and cells were counted using a TC10 automated cell counter (Bio-Rad). Cells plated in remaining wells were given new media every 2-3 days for the duration of the experiment.
Western blot analysis
Protein lysates were made using MPER (Mammalian Protein Extraction Reagent, Pierce ThermoScientific) containing complete mini protease inhibitor cocktail (Roche), according to manufacturer's protocols. Protein concentrations were measured using the BCA Assay (Pierce, ThermoScientific). Equal protein volumes were loaded onto polyacrylamide gels, and transferred to 0.2 lm nitrocellulose using the Semi-Dry transfer system (BioRad). The following antibodies were used for western analysis: mouse monoclonal to AZI (1:1,000, clone HI-12, CosmoBio Co., LTD), rabbit polyclonal to ODC (1:500, 16061, Progen Biotechnik), rabbit polyclonal to AZ (1:250, Mitchell) and mouse monoclonal to Actin (1:10,000, Clone AC-15, Sigma). HRP-conjugated secondary antibodies were obtained from GE Healthcare (1:10,000). All western blots were developed with ECL Plus reagent (GE Healthcare) following manufacturer's directions.
qRT-PCR
RNA samples from various cell lines were harvested using RNeasy Mini kits (Qiagen), and 0.5 lg of each RNA sample was used for cDNA synthesis with the Superscript III First-Strand Synthesis System (Invitrogen). Real time quantitative PCR reactions were then performed using 1 ll cDNA and iQ SYBR Green Supermix (Bio-Rad) on an Opticon 2 instrument (Bio-Rad). The following cycling conditions were used: 95°C for 3 min followed by 45 cycles of 95°C for 15 s, 60°C for 15 s, 72°C for 30 s, 77°C for 1 s plate read, followed by 72°C for 5 min, melt curve from 65 to 98°C read every 0.2°C, 72°C for 5 min, 10°C for 5 min. Data points were collected using the MJ Opticon Monitor 3.1 program (Bio-Rad) and analyzed using the DCt method (Pfaffl 2001) . Expression of beta-2-microglobulin was used as a control. Primer sequences used for qRT-PCR include the following: AZI Forward 5
Immunofluorescence Cells were plated at 2 9 10 4 cells/well onto autoclaved glass coverslips previously coated with 10 lg/ml fibronectin solution (BD Biosciences). Cells were fixed with cold methanol at -20°for 10 min, and permeabilized with a solution of 0.25% Triton X-100 in PBS for 10 min. After blocking for 1 h at room temperature in 1% normal goat serum (Invitrogen)/PBS, cells were incubated in primary antibody. Antibodies used include mouse monoclonal to AZI (1:500, Cosmo Bio Co., LTD) and rabbit polyclonal to gamma-tubulin (1:500, T5192, Sigma). Cells were stained with primary antibody for 1 h at room temperature, washed with PBS, and stained with secondary antibodies for 1 h at 
Animal experiments
For xenograft studies, stable PC3M-LN4 and AT6.1 cells expressing shGFP, or two individual shRNAs to knockdown AZI were injected into the hind flank of 8-week-old male athymic (nu/nu) nude mice (Massachusetts General Hospital). A total of 10 mice were used for each cell line. All cells were injected at 1 9 10 6 cells/mouse either with (PC3M-LN4) or without (AT6.1) Matrigel (BD Biosciences). Following the injection, tumor growth was measured twice per week by caliper. Tumor volume was calculated using the equation 1/2 9 (length 9 width 2 ). At the end of the experiment, all animals were humanely euthanized, tumors were excised, and tumor weights were measured. All animals were kept in specific pathogen-free housing and given abundant food and water under guidelines approved by the Children's Hospital Boston Animal Care and Use Committee.
SAGE and Oncomine analysis
Expression of AZI transcripts in normal versus cancer tissue was analyzed using the SAGE (Serial Analysis of Gene Expression) Digital Northern from the National Cancer Institute's Cancer Genome Anatomy Project (CGAP) at the website http://www.cgap.nci.nih.gov/SAGE. For AZI, the SAGE Genie program assigned the following unique identifying sequence: TCTTTCACCC from the 3 0 UTR. The SAGE library database was then analyzed for the number of AZI-specific hits for every 200,000 hits in the library. AZI expression was directly compared between normal prostate epithelial tissue and prostate carcinoma (PC3).
AZI expression in tumor tissue was also analyzed using the Oncomine database (http://www.oncomine.org) and the filter ''Cancer vs. Normal Analysis'' to detect changes in DNA copy number.
Statistical analysis
Statistical analysis was performed using one-way analysis of variance (ANOVA) or Kruskal-Wallis one-way analysis of variance tests in SPSS. Where appropriate, results were analyzed using two-tailed student's t test in Microsoft Excel 2003 at the 95% confidence level. If initial results showed that a statistically significant difference was detected between various groups, post hoc tests were used to identify which groups gave significantly different results. In each case, the Tukey's HSD (Honestly Significant Difference) statistic was determined, and the corresponding p value was reported. In all cases, p \ 0.05 was considered statistically significant.
Results

Expression of AZI in prostate cancer
Our laboratory has previously shown that manipulating the levels of AZI in numerous prostate cancer cell lines has a direct effect on rates of cell proliferation (Newman et al. 2004; Kim et al. 2006) , and cells possessing a higher AZI:AZ ratio have increased rates of cell growth. To explore whether AZI levels are elevated in prostate cancer, we analyzed SAGE (Serial Analysis of Gene Expression) data and data from Oncomine. As shown in Fig. 1 , AZI levels were significantly elevated (p = 0.011) in samples from prostate carcinoma as compared to normal prostate epithelium. We also used Oncomine to determine if AZI copy number was altered in various cancers. This analysis showed that AZI copy number is elevated in cancers of the breast and bone marrow, and may also be slightly elevated in prostate cancer. Based on our laboratory's long-term interest in prostate cancer, we chose to examine the role of AZI in two aggressive prostate cancer cell lines: human PC3M-LN4 cells and rat AT6.1 cells.
In vitro characterization of AZI knockdown cell lines PC3M-LN4 cells were transfected with control shRNA plasmids (empty vector pRS, shGFP), or two different shRNAs to knockdown AZI (shAZI H81, shAZI H84), and stable pools were generated. As shown by western blot, expression of either AZI shRNA led to a substantial decrease in protein levels of both AZI and ODC (Fig. 2a) , although the resulting effect on cellular polyamine levels was not determined. These results were confirmed at the mRNA level by quantitative real-time PCR (qRT-PCR), as shown in Fig. 2b . To determine if AZI knockdown led to a change in proliferation rates, we measured cell growth over a period of 7 days (Fig. 2c) . Knockdown of AZI with shAZI H81 led to a 23.6% reduction in cell growth, and knockdown with shAZI H84 resulted in a 31.4% reduction in vitro as compared to control cells expressing shGFP.
We further examined AZI levels in our shRNA cell lines by immunofluorescence microscopy (Fig. 2d) . Cytoplasmic AZI staining was reduced in both cell lines expressing shAZI, as compared to control shRNA, and representative images from pRS control cells and shAZI H84 knockdown cells are included. As we and others have previously reported, a portion of endogenous AZI localizes to the centrosome in several different cell lines (Mangold et al. 2008; Murakami et al. 2009 ). We observed that a portion of the endogenous AZI protein remained localized to the centrosome in all of our PC3M-LN4 stable cell lines, as seen by colocalization with the centrosome marker gammatubulin.
To extend these results to a second cell line, we made rat prostate AT6.1 cells stably expressing shRNA control plasmids (empty vector pRS, shGFP) or shAZI plasmids which target regions conserved in rat AZI protein (shAZI H83, shAZI M35). As shown by western blot in Fig. 3a , AZI knockdown with plasmid H83 led to decreased AZI protein levels, and a slight decrease was also observed with shAZI M35 as compared to control cells. Although only a slight decrease in AZI protein was observed with shAZI M35, qRT-PCR analysis confirmed that both shRNA sequences were effective at decreasing AZI mRNA levels (Fig. 3b) . When growth rates of AT6.1 control and shAZI cells were compared, shAZI H83 cells had a 24.4% decrease in cell proliferation and shAZI M35 cells showed a 17.0% decrease compared to shGFP cells after 6 days in culture (Fig. 3c) .
Knockdown of AZI decreases tumor growth in vivo
To determine whether cellular AZI levels are correlated with the ability of cells to promote tumor growth in vivo, we performed xenograft studies. shGFP control cells and two shAZI cell lines were implanted subcutaneously into nude mice. Results from the PC3M-LN4 shAZI cells are summarized in Fig. 4 . AZI knockdown with either shRNA led to decreased tumor growth compared to control shGFP cells (Fig. 4a) . shAZI H81 cells showed a 56.1% decrease in tumor growth in vivo, while shAZI H84 cells had a 43.5% decrease. This decrease in tumor size in shAZI cells also correlated with a significant decrease in end-tumor weights (shAZI H81, p = .031) (Fig. 4b) . Similar results were observed with AT6.1 cells stably expressing shAZI. AT6.1 cells expressing shAZI H83 had a 54.9% reduction in tumor growth compared to shGFP cells, and tumor growth in shAZI M35 cells was decreased by 35.8% (Fig. 5a ). As before, the decrease in tumor growth correlated with a decrease in tumor weight at the end of the experiment (shAZI H83, p = .011) (Fig. 5b) . We are currently analyzing tissue samples from shAZI and shGFP tumors to determine if AZI knockdown results in significant changes in cellular polyamine content. We are also currently analyzing whether AZI knockdown affects either microvessel density or cell invasiveness.
Discussion
Despite being cloned and sequenced over 10 years ago (Murakami et al. 1996) , very little is known about the functions of AZI outside of its role in polyamine biosynthesis. Like ODC, high levels of AZI promote increased polyamine production and increased cell growth, and a high intracellular ratio of AZI:AZ within the cell favors cell proliferation. Numerous lines of evidence indicate that AZI levels are elevated in various cancers, particularly prostate cancer, and our objective was to better understand how AZI contributes to neoplastic transformation. To date, only a few studies have addressed the role of AZI in vivo, and many of these reports focus on expression of AZI during the normal development (Murakami et al. 2010 ). Attempts to make AZI knockout mice established that homozygous AZI deletion results in neonatal lethality (Tang et al. 2009 ), and AZI -/-embryos are currently being characterized to better understand normal AZI function (Wan et al. 2010) .
The goal of this study was to explore the contribution of AZI to neoplastic transformation by determining whether AZI has a functional role in promoting prostate tumor growth in vivo. The experimental approach we chose was to make cells stably expressing AZI shRNA, and then characterize these cells with regard to cell proliferation rates in vitro, and subcutaneous tumor growth rates in vivo. We found that expression of AZI shRNA in PC3M-LN4 cells significantly decreased both AZI protein and mRNA levels. As expected, depletion of intracellular AZI resulted in decreased rates of cell proliferation in vitro. When PC3M-LN4 shAZI cells were used for xenograft experiments, both cell lines expressing AZI shRNA had substantially reduced tumor growth in vivo. Intriguingly, knockdown of AZI had a much greater effect on tumor growth in vivo, than on in vitro cell proliferation. In PC3M-LN4 cells the tumor growth in shAZI cell lines was reduced by an additional 1.39-to 2.38-fold compared to the in vitro data. This suggests that conditions in the tumor microenvironment may better support the growth of cells expressing high levels of AZI. One common way in which the microenvironment can influence tumor growth is through the balance between angiogenesis and hypoxic stress, and hypoxic conditions have recently been shown to directly influence polyamine levels. Culturing HeLa cells under hypoxic conditions in vitro enhanced polyamine uptake, increased ODC expression, and helped to protect cells against hypoxic stress (Svensson et al. 2008) . Interestingly, this effect was dependent on expression of AZI, a Human prostate cancer cells stably expressing either control shGFP or shAZI were injected subcutaneously into nude mice. 1 9 10 6 cells were injected in a 1:1 mix with Matrigel, and 10 animals were used for each cell line. Calipers were used to measure tumor size twice per week for 2 months, and tumor volume was calculated as previously described. As shown above, knockdown of AZI with shAZI H81 led to a 56% decrease in tumor growth in vivo, and knockdown with shAZI H84 resulted in a 44% decrease in tumor growth compared to control cells. b At the end of the experiment, tumors from each group were excised and weighed. Decreased growth of shAZI tumors was also detected as a decrease in end-tumor weight. shAZI H81 tumors had significantly decreased tumor weights (*p = .031) compared to shGFP control cells since cells treated with AZI siRNA no longer had increased polyamine levels after hypoxic treatment. It is possible that high levels of AZI in a developing tumor allow it to better overcome hypoxic stress, resulting in increased tumor growth in vivo. Our current studies analyzing microvessel density in shGFP compared to shAZI tumors will help us to determine how AZI knockdown affects angiogenesis in this model. To validate these results, we repeated these experiments in a second prostate cancer cell line, rat AT6.1 cells. Although AZI expression was not inhibited to the same degree as in the PC3M-LN4 cells, AT6.1 shAZI cells did exhibit both decreased cell proliferation in vitro, and significantly decreased subcutaneous tumor growth in vivo. Tumor growth in AT6.1 shAZI cell lines was reduced by an additional 2.11-to 2.25-fold compared to the in vitro data.
Historically, much of the focus on inhibiting the polyamine pathway in cancer has been centered on preventing ODC activity, (Shantz and Levin 2007; Tsuji et al. 1998; Meyskens and Gerner 1999; Basuroy and Gerner 2006) . We believe, however, that targeting AZI may prove to be a more useful therapeutic approach for tumor treatment. The reasons for this are twofold. First, due to such tight control of polyamine homeostasis, AZI is in a position to regulate flux through the entire polyamine pathway. Classically, drug targets are generally enzymes, but even though AZI has no enzymatic activity our results and previously published data have clearly shown that modulating AZI levels has a direct effect on both cell proliferation and polyamine levels. Second, AZI can promote cell proliferation not only through the polyamine pathway, but also by preventing AZ-mediated degradation of cyclin D1 (Newman et al. 2004) , as well as other proteins implicated in cell cycle regulation (Gruendler et al. 2001; Lim and Gopalan 2007) . Therefore, any strategy designed to inhibit AZI would likely result in affecting cell proliferation through both the polyamine pathway and through normal cell cyclin levels. Our preliminary data suggests that levels of cyclin D1 are slightly decreased in PC3M-LN4 shAZI cells compared to shGFP controls, and this may contribute to the decrease in cell proliferation we observed.
One of the limitations associated with using DFMO to inhibit ODC is that although DFMO can prevent cells from synthesizing their own intracellular polyamines, it does not prevent cells from taking polyamines up from the microenvironment. In contrast, inhibiting AZI may actually release AZ that could inhibit polyamine uptake. In the future, we plan to directly analyze polyamine uptake rates in our shGFP cells compared to the shAZI knockdown cell lines. The pathway involved in polyamine uptake in mammalian cells has not yet been fully characterized, and identifying the proteins involved could have a significant impact on the design of the current and future therapeutics (Palmer and Wallace 2010) .
In the future, we plan to use conditional knockdown models to further explore the function of AZI in tumor growth. One of the best models for these experiments would be to examine tumor growth in a genetically engineered mouse with conditional AZI knockdown. Our results showing that AZI knockdown can decrease prostate tumor growth in vivo add to the growing data that the AZI/ AZ pathway is a critical component involved in modulating cell proliferation and cell transformation. Furthermore, this data suggest that inhibiting AZI in neoplastic tissues may be beneficial for treatment of prostate cancer.
